Reviewing Ovid Therapeutics (NASDAQ:OVID) & Adhera Therapeutics (OTCMKTS:ATRX)

Ovid Therapeutics (NASDAQ:OVID) and Adhera Therapeutics (OTCMKTS:ATRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Ovid Therapeutics and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Adhera Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Ovid Therapeutics and Adhera Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25 million	58.44	-$17.41 million	($0.29)	-7.83
Adhera Therapeutics	N/A	N/A	N/A	($1.13)	N/A

Adhera Therapeutics has lower revenue, but higher earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ovid Therapeutics has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 11.38, indicating that its stock price is 1,038% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Ovid Therapeutics and Adhera Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1	0	7	1	2.89
Adhera Therapeutics	0	0	0	0	0.00

Ovid Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 125.77%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Ovid Therapeutics is more favorable than Adhera Therapeutics.

Insider & Institutional Ownership

72.2% of Ovid Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 28.2% of Adhera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Ovid Therapeutics beats Adhera Therapeutics on 7 of the 12 factors compared between the two stocks.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.